August 29, 2023

FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions

On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) wh...

The ASCO Post

February 21, 2024

FDA Approves Biweekly Teclistamab Dosing Regimen for Patients With Multiple Myeloma

On February 20, the FDA approved the supplemental biologics license application for teclistamab-cqyv (Tecvayli) for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed or r...

The ASCO Post

June 21, 2023

FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers

The U.S. Food and Drug Administration (FDA) announced a new voluntary pilot program to help physicians select safe and effective cancer treatments, with guidance on in vitro companion diagnostic tests...

The ASCO Post

March 14, 2024

FDA Approves Irinotecan Liposome as First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Today, the FDA approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.

The ASCO Post

February 07, 2025

FDA Approves Preparative Regimen for Allogeneic HSCT in Patients With AML or MDS

The FDA recently approved treosulfan (Grafapex), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric pat...

The ASCO Post

October 10, 2023

Accelerated Approval Granted for Use of Elranatamab-bcmm in Relapsed or Refractory Multiple Myeloma

FDA grants accelerated approval to elranatamab-bcmm for adults with relapsed or refractory multiple myeloma following the promising results of the MagnetisMM-3 trial.

The ASCO Post

February 18, 2024

Senator Tim Kennedy Joins Roswell Park Doctors, Patients Impacted by Sickle Cell Disease to Call for Expedited Medicaid Approval of New Gene Therapy Cures

Kennedy urges NYS Dept. of Health to expedite coverage of new, life-changing sickle cell cures

Roswell Park Comprehensive Cancer Center

July 19, 2023

FDA Grants Full Approval to Blinatumomab for MRD-Positive B-Cell Precursor ALL

On June 21, the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application for blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-...

The ASCO Post

February 15, 2023

FDA Approves Zanubrutinib for CLL or SLL

On January 19, the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocy...

The ASCO Post